Publications by authors named "G J Knight"
Purpose: To determine the adverse events (AEs) rate associated with percutaneous transhepatic biliary drainage (PTBD) and identify risk factors for their occurrence.
Materials And Methods: This single-center retrospective study included 2310 PTBD (right-side: 1164; left-sided: 966; bilateral: 180) interventions for biliary obstruction (benign/malignant) in 449 patients between 2010-2020. Patients with percutaneous cholecystostomy alone were excluded.
Article Synopsis
- Plasma p-tau217 is identified as a promising blood-based marker for detecting Alzheimer Disease (AD) pathology, particularly in memory clinic patients undergoing lumbar punctures.
- A study involving 108 participants found that plasma p-tau217 levels were significantly higher in those with detected amyloid (Aβ) pathology compared to those without, indicating its strong potential for diagnosis.
- The analysis showed that plasma p-tau217 had excellent performance metrics for Aβ detection (AUC: 0.91), outperforming other biomarkers and suggesting it could be a reliable tool in Alzheimer's diagnostics.
Background: Phenotypic data, such as the minimum inhibitory concentrations (MICs) of bacterial isolates from clinical samples, are widely available through routine surveillance. MIC distributions inform antibiotic dosing in clinical care by determining cutoffs to define isolates as susceptible or resistant. However, differences in MIC distributions between patient sub-populations could indicate strain variation and hence differences in transmission, infection, or selection.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the impact of switching to narrow-spectrum antibiotics for treating E. coli bacteraemia, evaluating changes in resistance rates, antibiotic usage, and mortality.
- The research employs a deterministic state-transition model with three scenarios to analyze outcomes over five years, highlighting trade-offs between resistance and survival rates.
- Findings suggest that while using the narrowest spectrum antibiotics can reduce resistance to second and third-line options, it may increase first-line resistance and mortality; however, optimizing treatment duration and reducing mortality rates are key to making this switch feasible.